These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 27144870)

  • 1. Reevaluating PSA Testing Rates in the PLCO Trial.
    Shoag JE; Mittal S; Hu JC
    N Engl J Med; 2016 May; 374(18):1795-6. PubMed ID: 27144870
    [No Abstract]   [Full Text] [Related]  

  • 2. Screening for prostate cancer: the current evidence and guidelines controversy.
    Gomella LG; Liu XS; Trabulsi EJ; Kelly WK; Myers R; Showalter T; Dicker A; Wender R
    Can J Urol; 2011 Oct; 18(5):5875-83. PubMed ID: 22018148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re: Reevaluating PSA Testing Rates in the PLCO Trial.
    Albers P
    Eur Urol; 2017 Feb; 71(2):300. PubMed ID: 27823819
    [No Abstract]   [Full Text] [Related]  

  • 4. More on Reevaluating PSA Testing Rates in the PLCO Trial.
    Pinsky P; Prorok P
    N Engl J Med; 2016 Oct; 375(15):1500-1501. PubMed ID: 27732807
    [No Abstract]   [Full Text] [Related]  

  • 5. More on Reevaluating PSA Testing Rates in the PLCO Trial.
    Shoag JE; Mittal S; Hu JC
    N Engl J Med; 2016 Oct; 375(15):1500-1501. PubMed ID: 27732806
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Reevaluating PSA Testing Rates in the PLCO Trial.
    Taneja SS
    J Urol; 2016 Oct; 196(4):1123-5. PubMed ID: 27628793
    [No Abstract]   [Full Text] [Related]  

  • 7. Lethal Prostate Cancer in the PLCO Cancer Screening Trial.
    Shoag J; Mittal S; Halpern JA; Scherr D; Hu JC; Barbieri CE
    Eur Urol; 2016 Jul; 70(1):2-5. PubMed ID: 27166670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Pinsky PF; Blacka A; Kramer BS; Miller A; Prorok PC; Berg C
    Clin Trials; 2010 Aug; 7(4):303-11. PubMed ID: 20571134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Knowledge, attitude and practice regarding prostate specific antigen (PSA) and prostate biopsy.
    Nazim SM; Raza SJ; Ather MH
    J Coll Physicians Surg Pak; 2013 Jul; 23(7):529-30. PubMed ID: 23823969
    [No Abstract]   [Full Text] [Related]  

  • 10. Prostate Cancer Screening - A Perspective on the Current State of the Evidence.
    Pinsky PF; Prorok PC; Kramer BS
    N Engl J Med; 2017 Mar; 376(13):1285-1289. PubMed ID: 28355509
    [No Abstract]   [Full Text] [Related]  

  • 11. The Melbourne Consensus Statement on the early detection of prostate cancer.
    Murphy DG; Ahlering T; Catalona WJ; Crowe H; Crowe J; Clarke N; Cooperberg M; Gillatt D; Gleave M; Loeb S; Roobol M; Sartor O; Pickles T; Wootten A; Walsh PC; Costello AJ
    BJU Int; 2014 Feb; 113(2):186-8. PubMed ID: 24206066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer: Prudent practice optimizes screening outcomes.
    Auvinen A
    Nat Rev Urol; 2016 Jul; 13(7):376-7. PubMed ID: 27215425
    [No Abstract]   [Full Text] [Related]  

  • 13. New PSA guidelines discourage overscreening.
    Peres J
    J Natl Cancer Inst; 2012 Jan; 104(1):8-9. PubMed ID: 22173585
    [No Abstract]   [Full Text] [Related]  

  • 14. [Prostate cancer screening: Reasons of controversy].
    Delporte G; Villers A; Penel N
    Bull Cancer; 2018 Dec; 105(12):1111-1118. PubMed ID: 30458966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications.
    Gershman B; Van Houten HK; Herrin J; Moreira DM; Kim SP; Shah ND; Karnes RJ
    Eur Urol; 2017 Jan; 71(1):55-65. PubMed ID: 26995328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The current state of prostate-specific antigen testing.
    Lewis R; Hornberger B
    JAAPA; 2016 Sep; 29(9):51-3. PubMed ID: 27575906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis of recommendations against prostate cancer screening with prostate specific antigen].
    Abascal Junquera JM; Fumadó Ciutat L; Francés Comalat A; Cecchini Rosell L
    Med Clin (Barc); 2016 Oct; 147(8):361-365. PubMed ID: 27085747
    [No Abstract]   [Full Text] [Related]  

  • 18. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians.
    Qaseem A; Barry MJ; Denberg TD; Owens DK; Shekelle P;
    Ann Intern Med; 2013 May; 158(10):761-769. PubMed ID: 23567643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guideline of guidelines: prostate cancer screening.
    Loeb S
    BJU Int; 2014 Sep; 114(3):323-5. PubMed ID: 24981126
    [No Abstract]   [Full Text] [Related]  

  • 20. Screening for prostate cancer: History, evidence, controversies and future perspectives toward individualized screening.
    Ito K; Oki R; Sekine Y; Arai S; Miyazawa Y; Shibata Y; Suzuki K; Kurosawa I
    Int J Urol; 2019 Oct; 26(10):956-970. PubMed ID: 31183923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.